Pacira BioSciences, Inc. (PCRX): Revenue
$726.41M
Year ended 2025-12-31
$746.16M
Trailing 12 months to 2026-06-30
+2.9%
3-year compound annual growth
+11.1%
5-year compound annual growth
| Period ended | Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $726.41M | +3.6% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $700.97M | +3.9% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $674.98M | +1.2% | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | $666.82M | +23.1% | 2024-02-29, From 2022-01-01 |
| 2021-12-31 | $541.53M | +26.0% | 2024-02-29, From 2021-01-01 |
| 2020-12-31 | $429.65M | +2.6% | 2023-02-28, From 2020-01-01 |
| 2019-12-31 | $418.93M | +26.0% | 2022-02-28, From 2019-01-01 |
| 2018-12-31 | $332.43M | +16.9% | 2021-03-01, From 2018-01-01 |
| 2017-12-31 | $284.34M | +5.3% | 2020-02-21, From 2017-01-01 |
| 2016-12-31 | $270.07M | n/a | 2019-02-28, From 2016-01-01 |
Revenue at similar companies
| Company | Year ended | Revenue | Change YoY |
|---|---|---|---|
| Pacira BioSciences, Inc. (PCRX) | 2025-12-31 | $726.41M | +3.6% |
| Amphastar Pharmaceuticals, Inc. (AMPH) | 2025-12-31 | $719.89M | -1.7% |
| Supernus Pharmaceuticals, Inc. (SUPN) | 2025-12-31 | $718.95M | +8.6% |
| Emergent BioSolutions Inc. (EBS) | 2025-12-31 | $742.90M | -28.8% |
| Corcept Therapeutics Inc (CORT) | 2025-12-31 | $761.41M | +12.8% |
| Kiniksa Pharmaceuticals International, plc (KNSA) | 2025-12-31 | $677.56M | +60.1% |
| Collegium Pharmaceutical, Inc (COLL) | 2025-12-31 | $780.57M | +23.6% |
| Ultragenyx Pharmaceutical Inc. (RARE) | 2025-12-31 | $673.00M | +20.2% |
| Axsome Therapeutics, Inc. (AXSM) | 2025-12-31 | $638.50M | +65.5% |
Compare PCRX, AMPH, SUPN, EBS side by side · Screen every company in Pharmaceutical Preparations ↗